Ten Indian stocks screened on five risk-and-return tests at once — and the screening trap that catches almost every first-time investor. Built for someone starting from zero in August 2026.
Data as of close, 23–24 July 2026 · Computed from NSE daily prices, adjusted for splits and bonuses · Research & education only — not investment advice
Where the market actually is
Nifty 50
23,870
▼ 9.3% off high
Sensex
76,391
▼ 11.0% off high
Nifty · 1 Year
−5.4%
2-yr CAGR −1.3%
Nifty · 3-Yr CAGR
6.5%
5-yr 8.5%
USD / INR
96.6
▼ 11.7% in 1 yr
RBI Repo
5.25%
MPC · 5 Aug
A reality check first. The Nifty has compounded at 6.5% a year over three years and is down over the last two. "25% proven returns, low risk" is not a category that exists — anything that returned 25%+ annually did so by taking real risk, and past 25% is not a forecast. What follows is the closest honest thing: businesses that compounded hard and held up better than average when the market fell.
Index
23-Jul-2026
1 Year
2-Yr CAGR
3-Yr CAGR
5-Yr CAGR
Nifty 50
23,869.6
−5.4%
−1.3%
+6.5%
+8.5%
Sensex
76,391.4
−7.7%
−2.5%
+4.6%
+7.6%
Nifty Bank
56,592.0
−1.1%
+4.5%
+7.1%
+10.1%
What is driving the fall
Crude above $95. The widening US–Iran conflict and Hormuz disruption. India imports ~85% of its oil — this hits inflation, the rupee and the fiscal maths at once.
FPI outflows. Roughly ₹2.3 lakh crore left Indian equities Jan–May 2026. On 23 July, FIIs sold ₹2,999 cr against DII buying of ₹2,947 cr — domestic funds are the only bid.
Weak Q1 FY27 bank earnings. Axis and HDFC Bank each fell ~6% on results, Kotak over 3%. Banks are ~20% of the Nifty.
Rupee at 96.6 plus rising US Treasury yields and a firm dollar, cutting the relative appeal of emerging markets.
Into the 5 August MPC
Repo held at 5.25% with a neutral stance since June, citing resilient domestic growth against external risks.
The bind: crude at $95 and a 96.6 rupee both feed inflation, arguing against a cut — while weak earnings and outflows argue for support.
Watch: the CPI prints, monsoon progress, and whether the US pharma tariff gets a formal proclamation.
Two sectors to treat carefully
IT is a structural de-rating, not a dip. The top-5 Indian IT companies have lost ~46% of combined market value since August 2024 — from ≈₹33.71 lakh cr to ≈₹18.15 lakh cr. For scale, Reliance alone is ₹17.65 lakh cr: the entire top-5 pack is now worth about one Reliance. Nifty IT is down ~32% in CY2026 against ~8% for the Nifty, at its lowest since May 2021. TCS cut roughly 23,000–25,000 jobs over FY26, including a single-quarter net decline of 11,151. TCS at 16× and Infosys at 13× look cheap — that is exactly what a de-rating looks like on the way down. Not a beginner's bottom-fishing trade.
US-export generic pharma has an unresolved tariff overhang. On 21 July 2026 a three-phase tariff on imported generics was announced — zero until August 2028, then 100% for a year, then 200%. No formal proclamation, legal basis or exemption list has been issued. About 35% of India's pharma exports go to the US, over 95% of it generics. Meanwhile the domestic Indian pharmaceutical market grew 16% YoY in June 2026, its strongest month in over two years. That split is why the pharma pick below is domestic-branded, not US-generic.
The ten
Screened from ~126 liquid NSE names on five tests simultaneously: 3-year CAGR, still compounding over 2 years, not falling over the last year, annualised volatility, and worst peak-to-trough drawdown. Then filtered by hand for sector spread and for exposure to the two risks above.
Stock
Business
Price ₹
3Y CAGR
2Y
1Y
Vol
Worst DD
P/E
Consensus
ICICI Bank
Private bank
1,433
14.0%
9.1%
−2.7%
18.9%
−18.4%
18.5
+21%
State Bank of India
PSU bank
1,015
20.2%
11.2%
26.7%
24.3%
−23.9%
11.1
+19%
Bharti Airtel
Telecom
1,898
30.1%
15.7%
−0.7%
20.8%
−18.8%
42.7
+21%
Eicher Motors
Royal Enfield, trucks
7,628
33.7%
26.1%
41.3%
25.4%
−19.6%
38.0
+5%
TVS Motor
2-wheelers, EV
3,870
44.2%
26.2%
38.8%
26.8%
−26.2%
53.8
+8%
Torrent Pharma
Domestic branded pharma
4,962
38.1%
26.8%
42.2%
22.5%
−17.0%
77.5
−1%
Apollo Hospitals
Hospitals, pharmacy
8,806
19.7%
17.4%
19.9%
21.1%
−18.5%
65.4
+7%
Marico
FMCG · Parachute, Saffola
856
18.2%
14.9%
22.2%
21.8%
−16.7%
62.9
+7%
Titan
Jewellery, watches
4,677
16.6%
16.3%
34.7%
22.3%
−22.5%
82.0
+8%
Cummins India High risk
Gensets, power equipment
5,601
45.6%
27.6%
59.2%
30.7%
−34.3%
65.8
Hold, +2%
Vol = annualised daily volatility over three years. Worst DD = largest peak-to-trough fall in that period — the number that tells you what you would have had to sit through. Consensus = analyst mean target versus current price. Only three names cleared 25% over three years while still compounding over two and one: Torrent, TVS and Cummins. The rest earn their place on drawdown control, not raw return.
Why each one is here
ICICI Bank — the lowest volatility in the entire screen at 18.9%, with the shallowest drawdown of any large bank. Flat over the past year, so you are not buying after a run. At 18.5× with 16% ROE, the closest thing here to a core holding.
SBI — 11× earnings, 20% three-year CAGR, up 27% over the last year while the Nifty fell. Cheapest large financial in India. PSU governance is the trade-off.
Bharti Airtel — 30% three-year CAGR at only 20.8% volatility, a rare combination. Domestic subscription revenue, real pricing power from tariff hikes, zero AI-disruption or US-tariff exposure. Flat over twelve months makes for a sane entry.
Eicher Motors — 34% / 26% / 41% across three, two and one year with a −19.6% worst drawdown and essentially no debt. Best quality per unit of risk on the list.
TVS Motor — the strongest two-wheeler franchise of the cycle, compounding on all three horizons. 54× earnings is the risk; buy in tranches, not at once.
Torrent Pharma — the best drawdown control in the screen at −17.0%, with India-domestic branded revenue that insulates it from the US generic tariff. The catch is a 77× P/E and negative trailing earnings growth. Priced for perfection.
Apollo Hospitals — the most consistent name here: ~20%, ~17%, ~20% over three, two and one year. Domestic healthcare demand, no export or currency risk. Expensive at 65×, as hospitals always are.
Marico — smallest drawdown of all ten at −16.7%, with a 41% ROE. This is the ballast: it will not double, and it will not halve either.
Titan — up 34.7% over the last year, helped by strong gold. Structural India consumption story with a 37% ROE. 82× is the most demanding valuation in the basket.
Cummins India — the highest return in the screen at 45.6% CAGR, and the highest risk: 30.7% volatility, −34.3% worst drawdown, 66× earnings, and analysts rate it only hold with 2% upside. Powers the data-centre and industrial capex theme. Size it smaller than the rest.
The 3-year CAGR trap
The single most useful thing in this piece. Several stocks show a beautiful three-year CAGR that is entirely an artefact of one explosive year in 2023–24, followed by two years of losses. A beginner screening on "three-year returns" alone walks straight into these.
Stock
3-Yr CAGR
2-Yr CAGR
Last 1 Yr
Worst Drawdown
IRFC
+38.1%
−31.3%
−34.2%
−58.6%
REC Ltd
+33.5%
−19.3%
−5.9%
−48.6%
Power Finance Corp
+33.8%
−7.9%
+1.2%
−37.6%
HAL
+34.5%
−1.8%
−1.1%
−44.5%
Trent
+19.2%
−26.0%
−43.8%
−73.3%
Every one of these passes a naive "25% for three years" filter. All five have lost money for anyone who bought two years ago. Trent fell 73% peak to trough. Always read the 2-year and 1-year columns next to the 3-year one. That single habit is worth more than any stock pick on this page.
Bench — good names left out
Federal Bank — 3Y 39%, 2Y 34%, drawdown only −18%. Excellent on the numbers, but up 68% in twelve months. Worth owning after a pullback.
Hindalco — 3Y 31% at a P/E of 15.7 with +18% consensus upside. Cheapest strong performer found, but commodity cyclicals are the wrong first stock.
Sun Pharma — lowest volatility in the whole universe at 19.4%. Held back only because the basket already carries two healthcare names.
Reliance — a three-year CAGR of just 1.4%, so it fails the screen entirely, yet carries the largest consensus upside on the board at +32% and benefits from high crude. A value idea, not a momentum one.
HDFC Bank — +38% consensus upside at 16.6×, but down 25% over the last year. Do not catch it until earnings stop deteriorating.
How to actually enter
Core before satellites. 60–70% into a Nifty 50 or Nifty 500 index SIP, with these ten as the remaining 30–40%. Ten stocks is not a diversified portfolio on its own.
Stagger over 6–8 months. Three unresolved events sit directly ahead: the 5 August RBI decision, the formal text of the pharma tariff, and crude at $95 with an active conflict. Split each position into 3–4 monthly buys.
Equal weight, one exception — halve Cummins; it is the only name with a −34% drawdown history.
Minimum horizon five years. Over three years the Nifty returned 6.5%; over five, 8.5%. Shorter horizons in this tape are a coin toss.
Set a review rule, not a price target. Revisit when the business breaks — two consecutive bad quarters, ROE falling below where you bought it, or the thesis ceasing to be true. Not when the price moves.
If you are investing from the UAE. This needs the NRI route — an NRE or NRO account linked to PIS (Portfolio Investment Scheme) permission from an Indian bank, plus an NRI demat. Capital gains are deducted at source for NRIs rather than self-declared, and repatriation limits differ between NRE and NRO. Confirm your residency status and the current LTCG/STCG rates with a CA before the first trade — the tax treatment, not the stock picks, is what usually catches first-time NRI investors.
Honest expected return. A realistic base case for this basket over five years is roughly 12–16% annualised, not 25%. Six of the ten trade above 50× earnings, which means the businesses can keep performing while the stocks still go nowhere for a year or two as valuations normalise. Expect at least one 20–30% drawdown somewhere in the holding period — every single name on this list has had one in the last three years.